New
HealthMore in Health→
Pfizer’s Monthly Obesity Drug Keeps Its Case Alive
New midstage data added to the case that Pfizer’s obesity drug, acquired from Metsera, may be suitable for monthly dosing.
Key Takeaways
- Detailed midstage data offered further evidence for monthly dosing.
- The obesity drug candidate entered Pfizer through its Metsera acquisition.
DE
DT Editorial Team··via statnews.com